The antiviral effect of ritonavir and saquinavir in combination amongst HIV-infected adults: Results from a community-based study

AIDS

Volumn 12, Issue 6, 1998, Pages 619-624

  Rhone, Stephanie A ^a   Hogg, Robert S ^a   Yip, Benita ^a   Sherlock, Chris ^a   Conway, Brian ^a   Schechter, Martin T ^a   O'Shaughnessy, Michael V ^a   Montaner, Julio S G ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antiretroviral therapy; Indinavir; Population based cohort; Protease inhibitors; Ritonavir; Saquinavir

Indexed keywords

CD4 ANTIGEN; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ANTIVIRAL ACTIVITY; ARTICLE; CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INSOMNIA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; NAUSEA; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RASH; TREATMENT OUTCOME; VERTIGO; VIRUS LOAD; VOMITING;

EID: 0032537171     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199806000-00011     Document Type: Article

References (29)

1. Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimetre or less. N Engl J Med 1997, 337:725-733.
2. Collier AC, Coombs RW, Schoenfeld DA, et al.: Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996, 334:1011-1017.
3. Cameron DW, Heath-Chiozzi M, Danner S, et al.: Randomized placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1998, 351:543-549.
4. Danner SA, Carr A, Leonard JM, et al.: A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995, 333:1528-1533.
5. Markowitz M, Saag M, Powderly WG, et al.: A preliminary study of ritonavir, an HIV-1 protease inhibitor, to treat HIV infection. N Engl J Med 1995, 333:1534-1539.
6. Kempf DJ, Marsh KC, Dennison JF, et al.: ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci USA 1995, 92:2484-2488.
7. Craig JC, Duncan IB, Hockley D, et al.: Antriviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. Antiviral Res 1991, 16:295-305.
8. Mathez D, Bagnarelli D, DeTruchis P, et al.: A triple combination of ritonavir + AZT + DDC as first line treatment of patients with AIDS. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoB175].
9. Kitchen VS, Skinner C, Ariyoshi K, et al.: Safety and activity of saquinavir in HIV infection. Lancet 1995, 345:952-955.
10. Kumar C, Marsh K, Rodriques D, et al.: Ritonaivr and saquinavir: potential for two-dimensional synergy between HIV protease inhibitors. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September 1995 [abstract LB7].
11. Cohen C, Sun E, Cameron W, et al.: Ritonavir-saquinavir combination treatment in HIV infected patients. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, September 1996 [abstract LB7b].
12. Merry C, Barry MG, Mulcahy F, et al.: Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997, 11:F29-F33.
13. Granneman GR, Hsu A, Sun E, et al.: Pharmacokinetics/pharmacodynamics of ritonavir-saquinavir combination therapy. Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 1997 [abstract 609].
14. Arvieux C, Michelet C, Bellisant E, et al.: Safety and efficacy of a combination of ritonavir and saquinavir added to AZT + 3TC. A pilote study, ANRS 069. IX Symposium on HIV Infection. Toulon, March 1997 [abstract OP8.1].
15. Cameron DW, Hsu A, Granneman GR, et al.: Pharmacokinetics of ritonavir-saquinavir combination therapy. Third International Congress on Drug Therapy in HIV Infection. Birmingham, November 1996 [abstract ss5.6].
16. Sun E, Xu Y, Hsu A, et al.: Predictability of response to ritonavir-saquinavir (RTV-SQV) combination therapy. Presented at AIDS Pathogenesis, Keystone Symposium. Keystone, April 1997.
17. British Columbia Centre for Excellence in HIV/AIDS: Therapeutic Guidelines for the Treatment of HIV/AIDS and Related Conditions. Vancouver: BC Centre for Excellence in HIV/AIDS; 1996.
18. World Health Organization: Acquired immune deficiency syndrome (AIDS): interim proposal for a WHO staging system for HIV infection and disease. Wkly Epidemol Rec 1990, 65:221-228.
19. Centers for Disease Control: Leads from the MMWR: revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. JAMA 1987, 258:1143-1154.
20. Neave HR, Worthington PL: Distribution-Free Tests. London: Routledge; 1998.
21. Emini EA, Schleif WA, Deutsch P, Condra JH: In vivo selection of HIV-1 variants with reduced susceptibility to the protease inhibitor L-735,524 and related compounds. Exp Med Biol 1996, 394:327-331.
22. sge) vs. Switching to Indinavir (IDV) After One Year of Saquinavir Use. ACTG 3 April 1997.
23. Bodsworth JN, Heaps M, Gosing D, et al.: Efficacy of Indinavir (IDV) and ritonavir (RTV) in patients pretreated with saquinavir (SQV). 7th Annual International Antiviral Symposium. Sydney, February 1997 [abstract 44].
24. Lorenzi P, Yerly S, Abderrakim KM, et al.: Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. AIDS 1997, 11:F95-F99.
25. Davis SM, Canniff JM, Andrads, et al.: Successful ritonavir induction: intensive patient management. Presented at the Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 1997.
26. Graham NH, Hoover DR, Park LP, et al.: Survival in HIV-infected patients who have received zidovudine: comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy. Ann Intern Med 1996, 124:1031-1038.
27. Delta Coordinating Committee: Delta: a randomized double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV infected individuals. Lancet 1996, 348:283-291.
28. Hammer SM, Katzenstein DA, Hughes MD, et al.: A trial comparing nucleoside monotherapy with combination therapy in HIV infected adults with CD4+ counts from 200 to 500 per cubic milliliter. N Engl J Med 1996, 335:1081-1090.
29. Carpenter CCJ, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV in 1997: updated recommendations of an international panel. JAMA 1997, 277:1962-1969.